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Abstract 
Background: Dexmedetomidine (DEX) is a centrally acting alpha-2-adrenoceptor agonist that has potential in the 
management of alcohol withdrawal syndrome (AWS) owing to its ability to produce arousable sedation and to inhibit 
the adrenergic system without respiratory depression. The objective of this randomized controlled study was to evalu-
ate whether addition of DEX to benzodiazepine (BZD) therapy is effective and safe for AWS patients in the intensive 
care unit (ICU).
Methods: Eligible participants were randomly assigned to intervention (Group D; n = 36) or control (Group C; 
n = 36). In Group D, DEX infusion was started at a dose of 0.2–1.4 μg/kg/h and titrated to achieve the target seda-
tion level (–2 to 0 on the Richmond Agitation Sedation Scale (RASS)) with symptom-triggered BZD (10 mg diazepam 
bolus) was used as needed. Patients in Group C received only symptom-triggered 10 mg boluses of diazepam. The 
primary efficacy outcomes were 24-h diazepam consumption and cumulative diazepam dose required over the 
course of the ICU stay; secondary outcomes included length of ICU stay, sedation and communication quality and 
haloperidol requirements.
Results: Median 24-h diazepam consumption during the study was significantly lower in Group D (20 vs. 40 mg, 
p < 0.001), as well as median cumulative diazepam dose during the ICU stay (60 vs. 90 mg, p < 0.001). The median 
percentage of time in the target sedation range was higher in Group D (median 90 % (90–95) vs. 64.5 % (60–72.5; 
p < 0.001). DEX infusion was also associated with better nurse-assessed patient communication (<0.001) and fewer 
patients requiring haloperidol treatment (2 vs. 10 p = 0.02). One patient in Group D and four in Group C were 
excluded owing to insufficient control of AWS symptoms and use of additional sedatives (p = 0.36). There were no 
severe adverse events in either group. Spontaneous breathing remained normal in all patients. Bradycardia was a 
common adverse event in Group D (10 vs. 2; p = 0.03).
Conclusions: DEX significantly reduced diazepam requirements in ICU patients with AWS and decreased the num-
ber of patients who required haloperidol for severe agitation and hallucinations. DEX use was also associated with 
improvement in diverse aspects of sedation quality and the quality of patient communication.
Trial registration: ClinicalTrials.gov: NCT02496650
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Background
Alcohol withdrawal syndrome (AWS) often complicates 
the perioperative period or critical illnesses and may 
increase the likelihood of admission to the intensive care 
unit (ICU). Up to 20 % of hospitalized patients have alco-
hol dependence and 18 % of these patients will develop 
AWS during their hospital stay [1]. The symptoms of 
AWS usually emerge 24–96  h after cessation of alco-
hol consumption and are characterized by sympathetic 
hyperactivity and metabolic and psychiatric disorders 
(e.g. agitation, hallucination and seizures). Benzodiaz-
epines (BZDs) are commonly used to manage AWS and 
are effective for that purpose. Several studies have shown 
that BZDs reduce the incidences of seizures and delirium 
and shorten the duration of AWS compared with placebo 
[2, 3]. However, BZD monotherapy may not be sufficient 
to control AWS symptoms [1], and administration of 
large doses is associated with excessive sedation, respira-
tory failure, worsening of delirium, increased aspiration 
and intubation risks, increased length of hospitalization 
and increased hospital costs [3, 4]. Furthermore, chronic 
liver disease patients are at risk of oversedation and pro-
gression of hepatic encephalopathy while using BZDs [5].
Alternative drugs with good efficacy and safety profiles 
are currently unavailable for the management of AWS 
[6]. Anticonvulsants, antipsychotics, ethanol, barbitu-
rates and propofol have historically been used for this 
purpose [7, 8], but the evidence base for these agents is 
weak or absent [6]. There have also been several studies 
of clonidine as adjunct treatment for AWS in the ICU. 
Significant decreases in AWS symptoms [9] and BZD 
doses [10] were reported, but with greater risk of adverse 
events such as bradycardia and hypotension [10, 11]. Dis-
advantages of clonidine include that it produces only a 
mild sedative effect (but with a significant hemodynamic 
impact) and its long duration of action (up to 12–16 h) 
[7].
Dexmedetomidine (DEX) is a selective, central ɑ2-
receptor agonist which is approved for ICU sedation in 
mechanically ventilated patients and for procedural seda-
tion for non-intubated patients [12]. Compared with 
clonidine, DEX offers more effective sedative and anal-
gesic properties, a shorter half-life (2–3  h) and signifi-
cantly lower rates of hemodynamic complication [12, 13]. 
Moreover, DEX does not cause respiratory depression 
and decreases the duration of mechanical ventilation [12, 
13].
There have been various reports of the successful use 
of DEX—usually as an adjunct to BZDs—in the manage-
ment of AWS during the last 10  years. However, most 
publications have been limited to case reports [14], case 
series [15] and retrospective [1] and prospective observa-
tional studies [16]. Only one randomized controlled study 
has been published to date [17], in which the authors 
found that adjunct use of DEX was associated with DEX 
attenuation of AWS symptoms, with concomitant reduc-
tions in use of BZDs. The commonest side effects were 
hypotension and bradycardia.
The objective of this randomized controlled study was 
to evaluate whether addition of DEX to BZD therapy 
is effective and safe for AWS patients in the ICU. We 
hypothesized that DEX would reduce BZD consumption 
and the need for neuroleptics, as well as improving seda-
tion quality.
Methods
This randomized, single-center, controlled study was 
conducted in the adult mixed ICU at the private hospital 
‘Boris’ in Kiev, Ukraine. The inclusion criteria were: age 
≥18–75 years and AWS diagnosed by means of the Diag-
nostic and Statistical Manual of Mental Disorders, 4th 
Edition criteria [18], plus the signed informed consent 
of either the patient or the patient’s family or a legal rep-
resentative. The exclusion criteria were age outside the 
specified range, history of use of other psychoactive sub-
stances or of withdrawal states, general anesthesia during 
the previous 24 h or other sedatives used, severe neuro-
logic disorder (traumatic brain injury, acute stroke, severe 
dementia), pregnancy or lactation, severe comorbidities 
(severe heart failure, acute myocardial infarction, heart 
rate <50 beats/min, glomerular filtration rate <30  mL/
min, liver failure Child-Pugh class C, acute respiratory 
failure) and known allergy to the study medication.
Typical reasons for ICU admission were severe agi-
tation, hallucinations, Clinical Institute Withdrawal 
Assessment of Alcohol Scale, Revised (CIWA-Ar) score 
≥15, history of seizures or previous delirium tremens 
(DT), coexisting medical problems (e.g. pancreatitis) or 
respiratory distress.
After the primary patient assessment, eligible par-
ticipants were assigned in a 1:1 ratio to either the inter-
vention (Group D) or control (Group C) groups using 
random assignment in blocks of four. The randomization 
sequence was generated using a computer algorithm [19]. 
Randomization and data analysis were conducted by an 
independent blinded member of the research team.
In Group D, DEX infusion was started at a dose of 
0.2–1.4  μg/kg/h and titrated to achieve the target seda-
tion level of –2 to 0 on the Richmond Agitation Seda-
tion Scale (RASS) and CIWA-Ar score <15. DEX loading 
doses were not used. Dosing and duration of DEX infu-
sion were adjusted by the clinical management team 
based on sedation assessment (with duration of DEX 
infusion no longer than 72  h). In patients for whom 
increasing the DEX infusion rate to 1.4 μg/kg/h did not 
achieve RASS −2 to 0 and/or a CIWA-Ar score of <15, 
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diazepam (10  mg i.v.) was administered according to 
a symptom-triggered protocol. In Group C, the same 
symptom-triggered diazepam regimen protocol was 
used. In both groups diazepam was administered every 
30 min as needed to control active withdrawal symptoms 
(CIWA-Ar score ≥15 or RASS score >+2), as prescribed 
by the clinical management team. Antipsychotics (i.m. 
haloperidol, 5 mg boluses) were used as a rescue medica-
tion in both groups for severe agitation or hallucinations. 
Haloperidol was prescribed only if the QT interval (QTc) 
was documented to be normal. No other sedatives or 
analgesics were allowed during the study period.
The primary efficacy outcomes were median 24-h diaz-
epam consumption and median cumulative diazepam 
dose required over the course of the ICU stay.
Secondary efficacy outcomes included:
  • length of ICU stay and intubation rates;
  • sedation quality: time in the target sedation range 
[RASS score 0 to −2] as a proportion of total seda-
tion time; the duration of insufficient sedation: time 
with RASS score ≥+2 as a proportion of total seda-
tion time; the duration of oversedation : time with 
RASS score ≤–3] expressed as a proportion of total 
sedation time; and the number of rescue sedation 
boluses and sedation stops required over a 24-h 
period;
  • the ability to communicate, such as asking for help or 
answering questions on comfort and pain, which was 
assessed by nurses during each shift (every 12 h) on a 
scale from 0 to 10, where 0 = uncommunicative and 
10 = patient communicates well;
  • haloperidol requirements (number of patients who 
received haloperidol for severe agitation and halluci-
nations) and cumulative haloperidol dose.
During their ICU stay, patients in both groups were 
evaluated by the nursing staff using the RASS and 
the CIWA-Ar scale (either every 2  h or prior to rescue 
therapy). The level of alertness was assessed using the 
Observer’s Assessment of Alertness/Sedation (OAA/S) 
scale every 2 h.
Safety was assessed by monitoring vital signs, perform-
ing laboratory tests (partial oxygen pressure in arterial 
blood [PaO2], partial carbon dioxide pressure in arte-
rial blood [PaCO2], oxygen saturation in arterial blood 
[SaO2], blood glucose) and recording adverse events. 
Continuous invasive measurement of blood pressure 
and pulse and continuous electrocardiogram monitoring 
was performed for all patients. QTc monitoring was pro-
vided for patients treated with haloperidol. Spontaneous 
breathing was assessed using continuous respiratory rate 
monitoring and pulse oximetry. Arterial blood gases were 
checked every 12 h or less as determined by the attending 
clinician.
An adverse event was recorded if systolic blood pres-
sure was <90 or >160 mmHg or if heart rate was <50 or 
>110 beats/min; desaturation was estimated as peripheral 
oxygen saturation (or SaO2) <90  %; hypoglycemia was 
defined as serum glucose <3.9  mmol/L and hypergly-
cemia as serum glucose >10  mmol/L. Interventions for 
bradycardia, tachycardia, hypertension and hypotension 
comprised titration or interruption of study agent, or 
additional drug therapy.
Statistical analysis was performed using Statistica 8.0 
and R software (StatSoft Inc., Tulsa, OK, USA). Cat-
egorical data are presented as proportions and continu-
ous data as medians with 25–75  % interquartile ranges 
(IQRs). Chi square testing demonstrated that all of the 
study variables were discrete. To assess significance lev-
els, a two-tailed Mann–Whitney U test and Fisher’s 
exact test were used. A p value of <0.05 was considered 
significant.
This study was approved by the Bogomolets National 
Medical University ethics committee (approval code 
number 84).
Results and discussion
A total of 72 patients were randomized to the study 
groups (n = 36 per group). The median time from hos-
pital admission to the start of the study was 24  h (IQR 
12–48 h) in Group D and 30 h (IQR 20–50 h) in Group C 
(p = 0.9). There were no significant differences between 
the study groups regarding demographic characteristics, 
comorbidities, initial AWS severity and diazepam dose 
administered prior to study enrollment.
Baseline characteristics of the study population are 
presented in Table 1.
The median duration of DEX infusion was 36  h (IQR 
24–42  h) with a median dose of 0.5  μg/kg/h (IQR 0.4–
0.8 μg/kg/h). All patients survived to discharge (Fig. 1).
The main outcomes of the study are presented in 
Table 2 and Fig. 2. As shown therein all the pre-specified 
dimensions of AWS symptomatology, BZD consumption, 
sedation quality, patient alertness and ability to com-
municate and use of rescue medications were favorably 
influenced by the use of DEX.
In this randomized controlled study, addition of DEX 
to BZD therapy significantly decreased 24-h diazepam 
consumption and cumulative diazepam dose during the 
ICU stay in AWS patients.
Sedation quality, one of the secondary outcomes, dif-
fered significantly between the two groups across a range 
of outcome indices. The median time in the target seda-
tion range was significantly higher in Group D (Δ25  %; 
p < 0.001) and DEX infusion was associated with better 
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patient communication (Δ3 points; p < 0.001). The dura-
tion of excessive sedation, number of sedation stops, 
duration of insufficient sedation and number of rescue 
sedation boluses were all significantly higher in Group 
C (Table 2). CIWA-Ar psychometric values decreased in 
both groups with the course of AWS, with no significant 
differences in median values between the two groups.
The number of patients who received haloperidol as a 
rescue medication for severe agitation and hallucinations 
was lower in Group D (odds ratio 6.8, 95  % confidence 
interval 1.4–33). However, the cumulative dose of halo-
peridol during the ICU stay did not differ significantly 
between groups: median cumulative dose 50  mg (IQR 
40–55  mg) in Group D and 60  mg (IQR 40–65  mg) in 
Group C (p = 0.2). Other authors have reported signifi-
cant reduction in haloperidol use after addition of DEX 
[1, 20], although those studies were retrospective and 
had several design limitations. In the only controlled trial 
of DEX as adjunctive therapy for AWS reported to date, 
haloperidol consumption and doses were not studied 
[17].
The median length of ICU stay was 50 h (IQR 46–65 h) 
in Group D and 70  h (IQR 65–90  h) in Group C 
(p = 0.059). DT developed in one patient in Group D and 
four in Group C (p = 0.36). These patients were excluded 
from the analysis due owing to insufficient control of 
AWS symptoms with study medication (e.g. dexmedeto-
midine, diazepam, haloperidol) and other sedatives used 
(propofol), all of them were intubated for airway protec-
tion and respiratory support. To our knowledge, there is 
no robust evidence of benefit from DEX use in patients 
with DTs. One prospective trial reported benefits with 
Table 1 Demographic data and AWS severity at baseline
CIWA-Ar Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised, IQR interquartile range, NYHA Ne``w York Heart Association Functional Classification
Group D (DEX) Group C (control) p value
Male 33/35 (94) 28/32 (88) 0.9
Age, median (IQR) 46.5 (43–50) 46 (42–50) 1.0
Comorbidity
 Liver cirrhosis
  Child-Pugh A, n (%) 1/35 (3) 1/32 (3) 1.0
  Child-Pugh B, n (%) 2/35 (6) 1/32 (3) 0.9
Pneumonia, n (%) 1/35 (3) 0/32 1.0
Diabetes, n (%) 1/35 (3) 2/32 (6) 0.9
Congestive heart failure
 NYHA class I 1/35 (3) 1/32 (3) 1.0
 NYHA class II 1/35 (3) 1/32 (3) 1.0
Arterial hypertension n (%) 3/35 (9) 6/32 (19) 0.19
Other
 Leg fracture, n (%) 2/35 (6) 0/32 1.0
 Acute pancreatitis, n (%) 1/35 (3) 2/32 (6) 1.0
CIWA-Ar at ICU admission, median (IQR) 25 (18 to 29) 26 (17–28) 1.0
RASS at ICU admission, median (IQR) +2 (+1 to +3) +2 (+1 to +3) 1.0
Diazepam dose administered prior to study enrollment, mg, median (IQR) 30 (20–40) 30 (20–40) 1.0
Meeng inclusion criteria, provided 
consent n=87 
Excluded n=15 
planned surgery -1  
other sedaves used – 10 
psychoacve drug used – 2 
liver failure C.-P. class C – 1 
heart rate <50/min 
Randomized n=72
Group D (DEX)  
n= 36
Group C (Control) 
n=36
1 excluded due to 
insufficient 
symptoms control 
& other sedaves 
used 
4 excluded due to 
insufficient 
symptoms control 
& other sedaves 
used 
Analyzed n=35 Analyzed n=32 
Fig. 1 CONSORT flowchart
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addition of DEX to BZD therapy in patients with DT [16]. 
However, that study had significant limitations: there 
was no comparison or control group and delirium was 
defined using the Confusion Assessment Method for the 
Intensive Care Unit (CAM-ICU), with no clear distinc-
tion between delirium caused by AWS and other factors.
Spontaneous breathing remained normal during the 
study period in all patients; desaturation was successfully 
treated with administration of extra oxygen and sedative 
drug titration. There were no statistically significant dif-
ferences between Groups D and C regarding desaturation 
incidence (Table 3), respiratory rate and arterial PaO2 or 
PaCO2.
No severe adverse events were identified (Table 3). The 
commonest adverse events observed were hypotension, 
hypertension and desaturation, with similar incidence 
in study groups; bradycardia, which was observed sig-
nificantly more often in Group D (p = 0.01); and tachy-
cardia, which was observed significantly more often in 
Group C (p =  0.02). Hospital-acquired pneumonia was 
diagnosed in one patient in Group D and two in Group 
C. No seizures were observed during the study.
After ICU discharge, patients continued treatment in 
the general department ward with oral diazepam. The 
median duration of hospitalization was 9  days (IQR 
8–10 days) in Group D and 11 days (IQR 10–13 days) in 
Group C (p = 0.034).
DEX is an attractive drug for AWS management owing 
to its ability to produce arousable sedation and to inhibit 
the adrenergic system without respiratory depression 
[12]. The benefits of DEX in AWS management have 
been shown in several retrospective series [1, 13–15]. 
Rayner et  al. [1] published a retrospective review of 
20 AWS patients admitted to the ICU, with DEX being 
used in addition to BZDs. The mean dose of DEX was 
0.53  µg/kg/h and the mean duration of therapy was 
49.1  h. Adjunctive DEX decreased severity score, halo-
peridol use and diazepam dose within 4  h. Dailey et  al. 
[21] published a retrospective chart review of 10 patients 
with AWS who were treated with DEX. The mean dose 
was 0.7  µg/kg/h and the mean infusion time was 50  h. 
The authors reported a significant diazepam dose reduc-
tion from 13 mg/h prior to DEX infusion to 3 mg/h in the 
24 h after treatment. All patients in the study had normal 
spontaneous breathing. Other studies have reported sim-
ilar results, although the majority of them were observa-
tional or retrospective [14–16].
To date only a few prospective controlled studies of use 
of DEX in AWS patients have been published [16, 17]. 
The authors of that research concluded that DEX shows 
promise as an adjunct to BZDs but concluded that fur-
ther studies are needed to fully profile the clinical impact 
of DEX in AWS. Our own study is a modest addition to 
the dataset of prospectively derived data and is support-
ive of earlier conclusions but it is still necessary to con-
duct larger randomized trials of DEX in AWS.
Table 2 Efficacy outcomes in study groups
Value expressed as medians (Interquartile Ranges 25 to 75), unless otherwise specified
No number, OAA/S Observer’s Assessment of Alertness/Sedation
Group D (DEX) Group C (control) p value
Diazepam consumption in 24 h, mg 20 (20–30) 40 (40–50) <0.001
Cumulative diazepam consumption, mg 60 (50–60) 90 (80–100) <0.001
Time of target sedation, % 90 (90–95) 64.5 (60–72.5) <0.001
Time of insufficient sedation, % 7.75 (5–10) 15 (10–20) <0.001
Time of oversedation, % 2 (0–5) 15 (10–20) <0.001
Rescue sedation boluses, no. in 24 h 1.25 (0–4) 4 (3–6) 0.004
Sedation stops, no. in 24 h 0 (0–1) 2 (0–3) 0.001
Communication with patient 9 (7–10) 6 (5–6) <0.001
OAA/S scale 1 (0–2) 2 (1–4) 0.03
Haloperidol use, no. of patients (%) 2/32 (6) 10/32 (31) 0.02
Median cumulative haloperidol dose, mg 50 (IQR 40–55) 60 (IQR 40–65) 0.2
Fig. 2 Diazepam 24-h consumption and cumulative dose during ICU 
stay
Page 6 of 7Bielka et al. Ann. Intensive Care  (2015) 5:33 
The limitations of this study include the partially 
blinded design with absence of placebo control and the 
small sample size (n = 72), which make it difficult to draw 
definitive conclusions. The exclusion of all patients who 
developed DT precludes any conclusions of the effective-
ness of DEX in that situation but the indications are that 
it adds little to the treatment options for that aspect of 
AWS.
Nevertheless, this trial supports adjunctive DEX use for 
many AWS patients in the ICU and provides efficacy and 
safety outcomes. In the authors’ opinion, we now have 
enough data to consider DEX as a valid adjunct to BZD 
therapy for AWS patients in the ICU. However, we need 
more data and new large studies before definite medi-
cal conclusions can be reached and the question of cost-
effectiveness has still to be addressed.
Conclusions
Addition of DEX to BZD therapy is effective and safe for 
AWS patients in the ICU. DEX appears to significantly 
reduce diazepam requirements as well as improve both 
sedation quality and patient communication. Addition of 
DEX to diazepam decreased the number of patients who 
required haloperidol for severe agitation. Monitoring for 
bradycardia is necessary during DEX infusion.
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